Balyasny Asset Management L.P. and related entities filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 944,265 shares of Cellectar Biosciences, Inc. common stock, representing approximately 9.99% of the class as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the five reporting persons discloses beneficial ownership of 944,265 shares of Cellectar Biosciences common stock.
  • Percent of class: The 944,265 shares represent approximately 9.99% of outstanding shares, based on 9,452,108 shares outstanding as of August 11, 2026.
  • Share composition: According to the filing, the reported amount consists of 220,000 direct shares and 724,265 shares issuable upon the exercise of 1,289,432 warrants, subject to a Beneficial Ownership Limitation.
  • Beneficial Ownership Limitation: The filing states the warrants are subject to a blocker preventing exercise to the extent the holder would beneficially own more than 9.99% of outstanding shares as a result.
  • Sole voting and dispositive power: Each reporting person reports sole voting power and sole dispositive power over all 944,265 shares, with zero shared voting or dispositive power.
  • Triggering event date: The date of the event requiring the filing is reported as September 30, 2026.
  • Five reporting persons: The filing is made jointly by Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, all headquartered at 444 West Lake Street, 50th Floor, Chicago, IL 60606.

Balyasny Asset Management's Amended 13G Filing for Cellectar Biosciences

The amended Schedule 13G covers Cellectar Biosciences, Inc. (NASDAQ:CLRB), whose principal executive offices are located at 100 Campus Drive, Florham Park, New Jersey 07932, according to the filing. The five reporting persons are linked through a chain of control: BAM GP LLC serves as the general partner of Balyasny Asset Management L.P.; Balyasny Asset Management Holdings LP is the sole member of BAM GP LLC; Dames GP LLC is the general partner of Balyasny Asset Management Holdings LP; and Dmitry Balyasny is the managing member of Dames GP LLC.

The filing states that Balyasny Asset Management L.P. acts as investment manager of Atlas Private Holdings (Cayman) Ltd. ("APHC"), which is the direct holder of the shares. APHC directly holds 220,000 shares of common stock, with an additional 724,265 shares reportable as issuable upon exercise of 1,289,432 warrants, subject to the Beneficial Ownership Limitation. Each reporting person in the chain is described as being able to exercise voting and investment power over the shares held by APHC, and therefore may be deemed to beneficially own those shares.

The 9.99% ownership figure is calculated based on 9,452,108 shares outstanding as of August 11, 2026, as reported in Cellectar Biosciences' Form 10-Q filed with the SEC on August 13, 2026, according to the Schedule 13G. The filing identifies the reporting persons' organization types as investment adviser and partnership (BAM), holding company and other (BAM GP and Dames), holding company and partnership (BAM Holdings), and holding company and individual (Dmitry Balyasny).

What Was Disclosed

Balyasny Asset Management L.P. and four affiliated entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of 944,265 shares of Cellectar Biosciences common stock, equal to approximately 9.99% of the class, triggered by an event on September 30, 2026.